30 closest matches · ranked by relevance
Thrombocytopenia Associated With Liver Disease
Primary: Percentage of Participants Who Did Not Require a Platelet Transfusion or Any Rescue Procedure for Bleeding After Randomization Following a Scheduled Procedure — 22.9…
Thrombocytopenia Associated With Liver Disease
Primary: Percentage of Participants Who Did Not Require a Platelet Transfusion After Randomization and up to 7 Days Following a Scheduled Procedure — 34.9; 68.6; 33.3; 87.9…
Thrombocytopenia
Primary: Number of Participants Who Achieved Platelet Response (Greater Than or Equal to 100 x 10^9/L) by Day 21 of Treatment Period A1 of Core Study — 1; 6; 12; 9 Participants…
Thrombocytopenia Associated With Chronic Liver Disease
Primary: Percentage of Participants With Platelet Count Greater Than or Equal to 50 x 10^9/L and at Least 20 x 10^9/L Increase From Baseline at Visit 4 — 9.1; 28.6; 63.6; 40.0…
Thrombocytopenia · Hematologic Diseases · Bone Marrow Aplasia
Primary: Number of Patients With Treatment-Emergent Adverse Events (TEAE) — 7; 6; 5 Participants
Chronic Liver Disease · Thrombocytopenia
Primary: Percentage of Participants Who Required No Platelet Transfusion Prior to the Primary Invasive Procedure and No Rescue Therapy For Bleeding From Randomization Through 7…
Liver Diseases
Primary: Change From Baseline in Platelet Counts on Day 15 — 24.8; 54.0; 60.0 10^9/Liter
Thrombocytopenia · Hematologic Diseases
Primary: Number of Participants With Platelet Count Recovery — 20; 22; 6 Participants
Thrombocytopenia Related to Chronic Liver Disease
Primary: Percentage of Participants Experiencing Response — 38.9; 31.3; 76.5; 6.3 Percentage of participants
Liver Disease
Primary: Number of Participants That Reached Targeted International Normalized Ratio (INR) Within ±0.1 After First Fresh Frozen Plasma (FFP) Transfusion Completed. — 7; 17…
Cirrhosis · Chronic Liver Disease
Primary: The Association of HVPG and PUD in Patients With Liver Cirrhosis — 14.5; 15.3 mmHg
Hepatitis C, Chronic
Primary: Number of Participants Whose Platelet Count Increased From a Baseline Count of < 80 Gi/L to a Count >=100 Gi/L During Part 1 — 43 Participants
Primary Immune Thrombocytopenia
Primary: Percentage of Participants With at Least One Grade 3 or Higher Treatment Emergent Adverse Event (TEAE), Treatment Emergent Serious Adverse Event (SAE), and TEAEs Leading…
Liver Fibrosis
Primary: Median Liver Stiffness Value — 7.70; 6.90 kPa — p=0.043
Nonalcoholic Fatty Liver · Nonalcoholic Steatohepatitis
Primary: Absolute Change in Intrahepatic Lipid Content, by 1H-MRS — -6.6; 3.6 Mean absolute percentage change
Cardiac Disease · Cardiac Surgery · Cardiopulmonary Bypass
Primary: Amount of Blood Products Transfused — 58; 103 milliliter per kilogram (mL/kg)
Hepatitis C, Chronic
Primary: Number of Participants With Sustained Virologic Response (SVR) in the Double-blind (DB) Antiviral Treatment Phase — 32; 97 participants — p=0.0202
Thrombocytopenia
Primary: At Least One Day With Grade 2 or Higher Bleeding — 304; 293; 299; 142 participants — p=0.83
Hepatitis C, Chronic
Primary: Number of Participants With Sustained Virologic Response (SVR) in the Double-blind (DB) Antiviral Treatment Phase — 33; 104 participants — p=0.0064
Thrombocytopenia
Primary: Comparing the Efficacy of Eltrombopaq and Placebo — 15; 5; 9; 0 Participants
Adrenal Insufficiency · Cirrhosis · Spur Cell Anemia
Primary: Number of Participants With Cholesterol Esterification Deficiency — 10; 11 Participants
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive · Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive · Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Primary: Number of Participants With a Platelet Response — 12; 0 Participants
Alloimmune Thrombocytopenia · Fetal Alloimmune Thrombocytopenia
Primary: Number of Newborns With a Birth Platelet Count > 50,000/uL — 48; 47 number of newborns with >50,000 pets
Blood Platelet Disorders
Primary: Response to Drug Based on Platelet Count at the End of Therapy — 91.6 percentage of participants
Liver Cirrhosis
Primary: Sensitivity and Specifity of Transient Elastography in Detection of Liver Cirrhosis — 0.83; 1.00; 1.00; 0.97 Probability
Immune Thrombocytopenia
Primary: Cumulative Number of Weeks of Platelet Response — 13.47 cumulative number of weeks
Liver Cirrhosis · Portal Hypertension
Primary: Admission Due to Complications Related to Portal Hypertension — 2; 3 participants — p=0.25
Thrombocytopenia
Primary: Bleeding Within 30 Days — 73; 78 Participants
Idiopathic Thrombocytopenic Purpura
Primary: Weeks With Weekly Platelet Response — 0.0; 11.0 Weeks — p=<0.0001
Immune Thrombocytopenia
Primary: Durable Platelet Response — 15; 0 Participants — p=0.0077